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Abstract
Background: The prevalence of anemia in HIV/ AIDS patients is high, with a multitude of possible
etiologies; autoimmune hemolytic anemia (AIHA) in HIV/AIDS patients has been associated with a poor
prognosis when treated with red cell transfusion. Our aim was to demonstrate the frequency of AIHA in
a cohort of adult Nigerian HIV/AIDS patients and to see if the presence or not of AIHA is related to the
severity of the disease with regards to the CD4 counts and the presence or absence of opportunistic
infections.
Method: Ninety- eight adult patients with HIV infection were screened for the presence of AIHA using
the packed cell volume (PCV), direct antiglobulin test (DAT) and reticulocyte count (RC).
Results: The frequency of AIHA was 3.06%, 36.74% of our study population were anemic; 11.22% had a
positive DAT. Mean RC was 2.22 +/ 0.90 for all the patients. There was no statistically significant
difference in the PCV of patients that had positive and negative DAT. There was no correlation between
the presence of AIHA, use of ART, presence of opportunistic infections or CD4 counts.
Conclusion: We conclude that in spite of the low frequency of AIHA in HIV/AIDS patients, the fact that
most patients will respond to standard treatment makes it imperative to screen HIV/AIDS patients with
anemia for the presence of AIHA. Again since HIV/AIDS patients with AIHA may have a fatal reaction to
red cell transfusion, we suggest that anemic patients with HIV/AIDS in non-emergency situations be
screened for the presence of AIHA before receiving red cell transfusions when indicated.
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Résumé
Culture générale: Il y a trop de fréquence d’anémie parmi les malades sero-positifs ou les malades
atteints de sida, souvent accompagne d’un grand nombres d’aetiologies: anémie haemolylique
autoimmuno (AHAI) parmi les malades sero-positifs est directement lie a une mauvaise pronostic,
surtout quand on fait le traitement avec une transformation du globule rouge. Notre objectif est de
démontrer la fréquence de (AHAI) parmi un nombre d’adultes nigérians sero-positifs ou qui sont
atteints du sida. C’est aussi de vérifier si la présence ou l’absence de (AHAI) est lie directement lie a la
gravite de la maladie, de la maladie surtout quand il s’agit de la numération CD4 et de la présence ou
absence des infections opportunistic.
Modalité: À l’aide de l’analyse directe antiglobulin (ADA) et la numération réticulocyte (NR) et le
packed cell volume (PCV) ; quatre-vingt-dix-huit malades sero-positifs, ont passé un test de dépistage
pour vérifier la présence de (AHAI)
Résultat: La fréquence de (AHAI) était 3.06%, 36.74% de notre population était anémique ; 11.22% était
positif de l’analyse antiglobulin.Pour la numération reticulocy, la moyenne était 2.22+\-0.90 pour tous
les malades, on n’a trouvé aucune différence qui est statistiquement significatif parmi les malades
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positif de (ADA) et négatif de (ADA). Il n y avait aucun rapport entre la présence de AHAI, l’emploi de
ART, présence des opportunistic ou la numération CD4.
Conclusion: Pour conclure, il faut souligner que, malgré la basse fréquence de AHAI dans les malades
atteint du sida ou sero-positifs, tous les sero-positifs avec anémie doivent passer un test de dépistage,
puisqu’il est évident que la plupart des malades réagissent positivement au traitement.Et en plus,nous
proposons que désormais, avant la transfusion du globule rouge, tous les malades sero-positifs ou du
sida, passent un test de dépistage afin de déterminer la présence de AHAI car parfois la prise de cette
transfusion peut aboutir à la mort.
Mots clés: autoimmuno, anémie, hémolyse, SIDA\VIH
Introduction
Infection with the human immunodeficiency virus
(HIV) which causes the acquired immunodeficiency
syndrome (AIDS) has remained a scourge in the
developing countries of the world; recent research
has shown that while only about 10% of the worlds
population lives in sub-Saharan Africa, the region is
home to about 64% of people living with HIV/AIDS
globally.
1
Nigeria has the largest population in Africa
and an HIV/AIDS prevalence of about 5%.
2
In spite of
the recent availability of antiretroviral therapy (ART)
at subsidized rates in Nigeria, only a small fraction of
patients are currently being treated. In fact, in 2005
only about 17% of persons in need of ART in sub-
Saharan Africa received It.
1
Anemia is prevalent among HIV/AIDS patients, it
is said to be present in 10%-20% of patients at initial
presentation and in over 70% over the course of the
disease.
3
Anemia in HIV/AIDS has multiple etiologies,
these include: decreased production following
suppression of hemopoiesis by lymphoma cells,
infections such as tuberculosis (TB) and inflammatory
cytokines; disseminated intravascular coagulation,
thrombotic thrombocytopenic purpura and immune
and non-immune hemolysis; or ineffective
production due to vitamin B12 or/ and folic acid
deficiency; made worse by therapy with Zidovudine
which is known to suppress erythropoiesis.
3
It is
certain that the presence of anemia in people living
with HIV worsens the prognosis since it is associated
with progression to AIDS
4
and shorter survival times
for HIV infected patients,
5
it has been shown that
anemia is a predictor of poorer prognosis for HIV
infected patients independent of the CD4 count.
6
Despite the high frequency of anemia and a
positive direct antiglobulin test (DAT) in these
patients, autoimmune hemolytic anemia (AIHA) is
less frequently diagnosed; this may be related to the
frequent lack of reticulocytosis
7
which makes the
diagnosis of AIHA more difficult, further complicated
in our environment by the fact that autoimmune
disorders are more common in Caucasians than the
indigenous African population. This finding may be as
a result of the endemicity of infectious and parasitic
diseases in Africa which impair hosts T-cell
immunity.
8,9
An earlier clinical and serological study
from Ethiopia confirmed that autoimmune diseases
are rare in many parts of Africa and concluded that
indigenous Africans that develop autoimmune
diseases may have hereditary predisposition.
10
Though more recent reports show that some forms
of autoimmune diseases may actually be more
common in Africans than earlier thought.
11
The




anemia is characterised by binding of anti-
erythrocyte autoantibodies to red cells and the
subsequent destruction of the coated cells in the
reticuloendothelial system.
8
Anemia in patients with HIV infection may
respond to treatment with ART, however, patients
who continue to have symptomatic anemia while on






are considered the first line treatments for AIHA in
immune competent patients, while splenectomy is
reserved for those cases that do not respond.
14
In
patients with HIV/AIDS and AIHA care must be taken
in placing them on steroids as it may further worsen
their immune suppression. Research has shown that
HIV/ AIDS patients with AIHA who receive red cell
transfusions have an increased risk of
thromboembolism which may be fatal.
15
People living
with HIV/AIDS with resolved anemia have been
shown to have a better prognosis than those with
anemia or those with anemia that did not respond to
therapy.
16
The aim of our study was to demonstrate the
frequency of AIHA among a cohort of adult HIV/AIDS
patients attending the HIV clinic in UBTH; and to see
if the presence or not of AIHA is related to the
severity of the disease with regard to the CD4 counts
of these patients and the presence or absence of
opportunistic infections.
Subjects and Methods
Ninety- eight unselected, consecutive, adult HIV
positive patients attending the outpatient clinic for
people living with HIV/AIDS at the University of Benin
Teaching Hospital were screened for the presence of
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AIHA using the packed cell volume (PCV), direct
antiglobulin test (DAT) and the reticulocyte count
(RC). They included: 48 males and fifty female
patients. Only patients who gave informed consent
were included in the study. For the purposes of this
study, presence of AIHA was defined as a PCV less
than 30%, positive DAT and a RC greater than 2.5%
Four milliliters of blood was withdrawn from each
patient by clean venepunture and placed in an EDTA
bottle for use in estimation of PCV, RC and DAT . PCV,
RC and DAT were carried out as previously
described.
17,18
While the mircrohemaocrit method
and new methylene blue reagent were used for PCV
and RC respectively; DAT was carried out as follows:
the test cells were washed four times with a
minimum of 3 ml of saline per wash, as much of the
supernatant as possible was removed after each
wash to achieve maximum dilution of residual serum
and then made up to 3% suspension in saline. Two
volumes of the antiglobulin reagent was added to
two volumes of the 3% cell suspension, the test tube
was immediately centrifuged after thorough mixing
and then read for agglutination. The same procedure
was repeated with Coomb’s positive and negative
cells as control for each batch.
Patients were interviewed and information
entered onto a standardized data form, additional
data such as the CD4 counts were extracted from the
case notes, patients who had not done a CD4 count
within the previous 4 weeks were excluded from the
study. The study was approved by the hospital’s
ethics committee.
Data collected in this study were analyzed on a
computer with SPSS (Statistical Package for Social
Sciences) software version 12.0. Means were
compared using the Students’ t test; level of
significance was taken as P<.05. The average values
are presented as mean +/ standard deviation (SD)
unless otherwise stated.
Results
Ninety-eight patients were involved in this study,
made up of 48(48.97%) males and 50(51.02%)
females respectively. Mean age for the study
population was 37.43 +/ 7.93 years; age and sex
distribution of the study population is shown in Table
1. Mean PCV was 31.62 +/ 5.94%. Three (3.06%)
patients met the study criteria for AIHA; eight other
patients had positive DAT, but did not meet the other
study criteria for AIHA. Mean PCV was 24.71+/
3.30% in patients with AIHA compared with 32.15+/
5.77% in those without AIHA, this was statistically
significant. Mean RC was 2.22 +/ 0.90% for all the
patients; it was 6.77+/ 0.45% in those positive for
AIHA and 1.96+/ 0.69% in those without AIHA, this
was also statistically significant. Table 2 shows the
result of laboratory parameters in different
categories of the study population.
Table 1. Age and sex distribution of the study population
Age (years) M (%) F (%) Total (%)
21-30 8 (8.16) 12 (12.25) 20(20.41)
31-40 28 (28.57) 23 (23.47) 51(52.04)
41-50 9 (9.18) 9 (9.18) 18(18.37)
51-60 3 (3.06) 6 (6.12) 9 (9.18)
Total 48 (48.97) 50 (51.02) 98(100)
Table 2. Laboratory parameters (mean+/SD) in different categories of the study population
Categories PCV (%) CD4 (cells/L) RC
AIHA 24.71+/ 3.30 161.0 +/ 37.57 6.77 +/ 0.45
No AIHA 32.15 +/ 5.77* 230.19+/ 119.97* 1.96+/ 0.69*
DAT positive 29.09+/ 6.67 153.73+/ 58.16 5.26+/ 2.18
DAT negative 31.62+/ 5.92 234.29 +/ 119.96 2.22+/ 1.91**
PTB 31.88+/ 7.00 203.21+/ 137.26 2.09+/ 1.63
No PTB 31.54+/ 5.60 232.39 +/ 110.17 2.24+/ 1.99
PCV: Packed cell volume; RC: reticulocyte count ; AIHA: autoimmune hemolytic anemia; DAT: direct antiglobulin test ; PTB: Pulmonary
tuberculosis
*P<.05 compared to AIHA
** P<.05 compared to DAT positive
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Thirty-six (36.74%) patients had anemia using the
study definition of PCV<30%. Eleven (11.22%)
patients were positive for DAT, those that were DAT
positive had a mean PCV of 29.09+/ 6.67% while
those that were DAT negative had a mean PCV of
31.62+/ 5.92%, as shown in Table 2. Mean CD4
count was 225.25 +/ 117.31 cells/ L; it
was153.73+/ 58.16 cells/ L for those that were
DAT positive and 234.29+/ 119.96 cells / L for
those that were negative; P>.05. Patients with AIHA
had a mean CD4 count of 161.0+/ 37.57 cells/L
compared with 230.19 +/ 119.97 cells/ L in those
without AIHA; P>.05
Twenty-four (24.49%) patients had pulmonary
tuberculosis (PTB) which was the only opportunistic
infection found in the patients we studied. There was
no statistically significant difference in CD4 counts
between patients with PTB and those without: 203.
21 +/ 137.26 cells/ L cells / compared with 232.39
+/ 110.17 cells/ L.
Eighty-one (82.65%) patients were already on
ART, which consisted of: Stavudine, nevirapine and
lamivudine. Eighty- eight (89.8%) patients were
infected with HIV-1 virus, 10(10.20%) with both HIV 1
and 2 viruses. No patient was found with only the
HIV-2 virus.
Discussion
Anemia was present in 36.74% of patients in this
study, this agrees with earlier studies which
concluded that anemia was a frequent complication
of HIV infection.
16
The frequency of AIHA in this study
is 3.06%. This value agrees with previous studies
which reported that AIHA is not frequently seen in
the HIV/ AIDS patient and may be as a result of the
difficulty in making a diagnosis as reticulocytosis is
often absent in HIV/AIDS patients with AIHA,
7
the
rather low frequency in our patients may also be
related to the low frequency of autoimmune
disorders in the black African.
8
Eleven (11.22%) patients in the study had positive
DAT, mean PCV among these patients was lower than
the mean PCV among the DAT negative group,
though this difference was not statistically significant,
it is in agreement with previous studies which have
shown that HIV/AIDS patients with positive DAT have
lower PCV.
19,20
Mean CD4 count was significantly lower in DAT
positive patients compared to DAT negative patients.
This may be as a result of the higher incidence of
immune dysregulation in patients with progressive
HIV/ AIDS, especially as it has been previously
suggested that there may be serological anti-
erythrocyte autoimmunity without hemolytic effects
in a large majority of HIV/ AIDS patients.
7
There was a statistically significant difference in
mean PCV, CD4 and RC counts in patients that had
AIHA and those that did not. Also patients without
AIHA had higher PCV and CD4 counts than those with
AIHA, this may suggest that patients with a lower
CD4 count are more likely to develop AIHA. However,
the fact that there was no correlation between AIHA
and the CD4 count and also between AIHA and the
presence of PTB infection, further confirms the
earlier finding that red cell autoantibodies may be
present in HIV patients in the absence of features
overt hemolysis.
20
There was no correlation between PCV and RC in
our study, this may be due to suppression of
erythropoiesis by the HIV virus or ART drugs.
We conclude that in spite of the fact that AIHA
may have a low prevalence in HIV/AIDS patients, the
fact that most patients will respond to standard
treatment and that those that do respond have a
good prognosis makes it imperative to screen
HIV/AIDS patients with anemia for the presence of
AIHA. Again it has been reported previously that
HIV/AIDS patients with AIHA may have a fatal
reaction to red cell transfusion, it becomes
imperative that anemic patients with HIV/AIDS in
non-emergency situations be screened for the
presence of AIHA before receiving red cell
transfusions when indicated.
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